Liver extracellular volume fraction values obtained with magnetic resonance imaging can quantitatively stage liver fibrosis: a validation study in monkeys with nonalcoholic steatohepatitis

Lyu, Liang; Liu, Xing Li; Rui, Mao Ping; Yang, Li; Wang, Guan Zhong; Ding, Fan; Wang, Tony; Zheng, Jie

doi:10.1007/s00330-020-06902-w

Cited by 3 publications

(2 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, cholesterol metabolism between humans and Baboons is remarkably similar ( 132 ), and baboons given a high-sugar, high-fat diet leads to weight gain and hyperlipidemia similar to humans ( 133 ). Cynomolgus monkeys given a diet containing 20% fat with 5% cholesterol developed NASH with fibrosis ( 134 ). In addition, a high-fat, high-cholesterol (1%) diet can accelerate NASH in Cynomolgus monkeys with spontaneously-developed NASH symptoms ( 135 , 136 ).…”

Section: Concurrent Modelling Of Nash and Atherosclerosismentioning

confidence: 99%

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease

Finney

Das

Kumar

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Therapeutic approaches that lower circulating low-density lipoprotein (LDL)-cholesterol significantly reduced the burden of cardiovascular disease over the last decades. However, the persistent rise in the obesity epidemic is beginning to reverse this decline. Alongside obesity, the incidence of nonalcoholic fatty liver disease (NAFLD) has substantially increased in the last three decades. Currently, approximately one third of world population is affected by NAFLD. Notably, the presence of NAFLD and particularly its more severe form, nonalcoholic steatohepatitis (NASH), serves as an independent risk factor for atherosclerotic cardiovascular disease (ASCVD), thus, raising interest in the relationship between these two diseases. Importantly, ASCVD is the major cause of death in patients with NASH independent of traditional risk factors. Nevertheless, the pathophysiology linking NAFLD/NASH with ASCVD remains poorly understood. While dyslipidemia is a common risk factor underlying both diseases, therapies that lower circulating LDL-cholesterol are largely ineffective against NASH. While there are no approved pharmacological therapies for NASH, some of the most advanced drug candidates exacerbate atherogenic dyslipidemia, raising concerns regarding their adverse cardiovascular consequences. In this review, we address current gaps in our understanding of the mechanisms linking NAFLD/NASH and ASCVD, explore strategies to simultaneously model these diseases, evaluate emerging biomarkers that may be useful to diagnose the presence of both diseases, and discuss investigational approaches and ongoing clinical trials that potentially target both diseases.

show abstract

Section: Concurrent Modelling Of Nash and Atherosclerosismentioning

confidence: 99%

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease

Finney

Das

Kumar

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…Therefore, liver extracellular volume (LECV) measured by CT or MR T1 mapping can also be used to assess liver fibrosis[ 75 - 77 ]. In a cynomolgus monkey model of NASH, Lyu et al [ 78 ] found that LECV was significantly correlated with the fibrosis score ( r = 0.949), and demonstrated an AUC of 0.945 in diagnosing liver fibrosis.…”

Section: Progression Of Diffuse Liver Diseasementioning

confidence: 99%

Noninvasive imaging of hepatic dysfunction: A state-of-the-art review

Duan¹,

Jiang²,

Ling³

et al. 2022

WJG

View full text Add to dashboard Cite

Hepatic dysfunction represents a wide spectrum of pathological changes, which can be frequently found in hepatitis, cholestasis, metabolic diseases, and focal liver lesions. As hepatic dysfunction is often clinically silent until advanced stages, there remains an unmet need to identify affected patients at early stages to enable individualized intervention which can improve prognosis. Passive liver function tests include biochemical parameters and clinical grading systems ( e.g ., the Child-Pugh score and Model for End-Stage Liver Disease score). Despite widely used and readily available, these approaches provide indirect and limited information regarding hepatic function. Dynamic quantitative tests of liver function are based on clearance capacity tests such as the indocyanine green (ICG) clearance test. However, controversial results have been reported for the ICG clearance test in relation with clinical outcome and the accuracy is easily affected by various factors. Imaging techniques, including ultrasound, computed tomography, and magnetic resonance imaging, allow morphological and functional assessment of the entire hepatobiliary system, hence demonstrating great potential in evaluating hepatic dysfunction noninvasively. In this article, we provide a state-of-the-art summary of noninvasive imaging modalities for hepatic dysfunction assessment along the pathophysiological track, with special emphasis on the imaging modality comparison and selection for each clinical scenario.

show abstract

MRI Extracellular Volume Fraction in Liver Fibrosis—A Comparison of Different Time Points and Blood Pool Measurements

Obmann,

Ardoino,

Klaus

et al. 2024

Magnetic Resonance Imaging

View full text Add to dashboard Cite

BackgroundExtracellular volume (ECV) correlates with the degree of liver fibrosis.PurposeTo analyze the performance of liver MRI‐based ECV evaluations with different blood pool measurements at different time points.Study TypeProspective.Sample73 consecutive patients (n = 31 females, mean age 56 years) with histopathology‐proven liver fibrosis.Field Strength/Sequence3T acquisition within 90 days of biopsy, including shortened modified look–locker inversion recovery T1 mapping.AssessmentPolygonal regions of interest were manually drawn in the liver, aorta, vena cava, and in the main, left and right portal vein on four slices before and after Gd‐DOTA administration at 5/10/15 minutes. ECV was calculated 1) on one single slice on portal bifurcation level, and 2) averaged over all four slices.Statistical TestsParameters were compared between patients with fibrosis grades F0‐2 and F3‐F4 with the Mann–Whitney U and fishers exact test. ROC analysis was used to assess the performance of the parameters to predict F3‐4 fibrosis. A P‐value <0.05 was considered statistically significant.ResultsECV was significantly higher in F3‐4 fibrosis (35.4% [33.1%–37.6%], 36.1% [34.2%–37.5%], and 37.0% [34.8%–39.2%] at 5/10/15 minutes) than in patients with F0‐2 fibrosis (33.3% [30.8%–34.8%], 33.7% [31.6%–34.7%] and 34.9% [32.2%–36.0%]; AUC = 0.72–0.75). Blood pool T1 relaxation times in the aorta and vena cava were longer on the upper vs. lower slices at 5 minutes, but not at 10/15 minutes. AUC values were similar when measured on a single slice (AUC = 0.69–0.72) or based on blood pool measurements in the cava or portal vein (AUC = 0.63–0.67 and AUC = 0.65–0.70).Data ConclusionLiver ECV is significantly higher in F3‐4 fibrosis compared to F0‐2 fibrosis with blood pool measurements performed in the aorta, inferior vena cava, and portal vein at 5, 10, and 15 minutes. However, a smaller variability was observed for blood pool measurements between slices at 15 minutes.Level of Evidence1Technical EfficacyStage 3

show abstract

Liver extracellular volume fraction values obtained with magnetic resonance imaging can quantitatively stage liver fibrosis: a validation study in monkeys with nonalcoholic steatohepatitis

Cited by 3 publications

References 45 publications

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease

The interplay between nonalcoholic fatty liver disease and atherosclerotic cardiovascular disease

Noninvasive imaging of hepatic dysfunction: A state-of-the-art review

MRI Extracellular Volume Fraction in Liver Fibrosis—A Comparison of Different Time Points and Blood Pool Measurements

Contact Info

Product

Resources

About